Here's Why Cencora (COR) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Cencora (COR) is Poised to Beat Earnings Estimates Again
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court
Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cencora: Long-Term Compounder With Mouth-Watering Economics
COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working capital benefits. I have updated my price objectives to $270-$285 with a long-term intrinsic valuation of over $360 per share.
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
